Globus Medical reported a slight decrease in net sales for Q1 2025 compared to the prior year, primarily due to softer Enabling Technology sales and international order timing, offset by strength in the US spine business. The company achieved GAAP net income and positive GAAP and non-GAAP EPS, alongside record Q1 free cash flow and a return to debt-free status.
Worldwide net sales decreased by 1.4% to $598.1 million in Q1 2025.
GAAP net income was $75.5 million for the quarter.
GAAP diluted EPS was $0.54 and non-GAAP diluted EPS was $0.68.
The company delivered record Q1 free cash flow of $141.2 million and paid off remaining debt from the NuVasive merger.
The company reaffirms its full-year 2025 revenue guidance but updated its non-GAAP fully diluted earnings per share guidance downwards.
Visualization of income flow from segment revenue to net income